FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
J. Clin. Oncol 2019 Oct 14;[EPub Ahead of Print], DP Modest, UM Martens, J Riera-Knorrenschild, J Greeve, A Florschütz, S Wessendorf, T Ettrich, S Kanzler, D Nörenberg, J Ricke, M Seidensticker, S Held, P Buechner-Steudel, J Atzpodien, V Heinemann, T Seufferlein, A Tannapfel, AC Reinacher-Schick, M GeisslerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.